Buprenorphine prior authorization review. The department shall review its prior authorization policy on buprenorphine-containing products provided to Medical Assistance program recipients. On the first day of the 7th month beginning after the effective date of this subsection .... [LRB inserts date], and every 6 months thereafter, the department shall submit to the standing committees of the legislature with jurisdiction over health under s. 13.172 (3) a report describing the department's findings on the prior authorization policy on buprenorphine-containing products and its progress on eliminating prior authorization requirements for buprenorphine-containing products in populations where removal of prior authorization is appropriate.
|Assigned Number||Title||Version Date||Publication Type||Other Location||Language|
|P-02294||Medicaid Prior Authorization Policy for Buprenorphine-Containing Products for Medication-Assisted Treatment, June 2019||July 10, 2019||
|P-02294||Medicaid Prior Authorization Policy for Buprenorphine-Containing Products for Medication-Assisted Treatment||December 13, 2018||